A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
Article Details
- CitationCopy to clipboard
Vaz RJ, Nayeem A, Santone K, Chandrasena G, Gavai AV
A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series.
Bioorg Med Chem Lett. 2005 Sep 1;15(17):3816-20.
- PubMed ID
- 15993593 [ View in PubMed]
- Abstract
A comparative molecular similarity index analysis (CoMSiA) has been performed for cytochrome P450 2D6 inhibition on a series of aryloxypropanolamines to determine the factors contributing to this activity. The model is in agreement with a CYP2D6 homology model constructed on the basis of the mammalian CYP2C5 crystal structure. The energy minimized conformations were generated using the systematic search methodology in Sybyl 6.7. The model not only elucidated the relationship between structure and biological activity but, more importantly, provided useful strategies to modulate CYP2D6 affinity in the aryloxypropanolamine series.
DrugBank Data that Cites this Article
- Binding Properties
Drug Target Property Measurement pH Temperature (°C) Betaxolol Cytochrome P450 2D6 IC 50 (nM) 66000 N/A N/A Details Metoprolol Cytochrome P450 2D6 IC 50 (nM) 24000 N/A N/A Details Propranolol Cytochrome P450 2D6 IC 50 (nM) 1900 N/A N/A Details Timolol Cytochrome P450 2D6 IC 50 (nM) 11000 N/A N/A Details